Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia

Supportive Care in Cancer

Volumn 21, Issue 8, 2013, Pages 2303-2308

  Ahn, Shin ^a   Lee, Yoon Seon ^a   Lim, Kyung Soo ^a   Lee, Jae Lyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Bacteremia; Febrile neutropenia; Procalcitonin; Septic shock

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; AGE; ARTICLE; BACTEREMIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER RISK INDEX SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; THROMBOCYTE COUNT;

EID: 84879890987     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1787-6     Document Type: Article

References (16)

1. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134
2. Hui EP, Leung LK, Poon TC, Mo F, Chan VT, Ma AT, Poon A, Hui EK, Mak SS, Lai M, Lei KI, Ma BB, Mok TS, Yeo W, Zee BC, Chan AT (2011) Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625-1635
3. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 16:475-483
4. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051
5. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51-S59
6. Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, Hansson LO, Tidefelt U (2004) Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 36:365-371
7. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32:1718-1725
8. Ahn S, Lee YS, Chun YH, Lim KS, Kim W, Lee JL (2012) Predictive factors of bacteraemia in low-risk patients with febrile neutropenia. Emerg Med J 29:715-719
9. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
10. Engel A, Steinbach G, Kern P, Kern WV (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31:185-189
11. Hambach L, Eder M, Dammann E, Schrauder A, Sykora KW, Dieterich C, Kirschner P, Novotny J, Ganser A, Hertenstein B (2002) Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica 87:643-651
12. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C (2006) Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 43:468-473
13. Ahn S, Lee YS (2012) Predictive factors for poor prognosis febrile neutropenia. Curr Opin Oncol 24:376-380
14. Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L (2011) Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 19:1001-1008
15. Feld R (2008) Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 32(Suppl 1):S30-S33
16. Ha YE, Song JH, Kang WK, Peck KR, Chung DR, Kang CI, Joung MK, Joo EJ, Shon KM (2011) Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer 19:1761-1767